Israeli pharmaceutical company Kamada has announced positive results of its Phase I/II clinical trial of the company’s AAT protein, the active ingredient in its drug Glassia. The results indicate that the drug may halt the progression of the disease and enable the pancreas to continue excreting insulin.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments